No Data
Health Check: How Prudently Does Innovative Medical ManagementLtd (SZSE:002173) Use Debt?
Innovative Healthcare: Third Quarter 2024 Report
Innovative medical management (002173.SZ) announced its performance for the first three quarters, with a net loss of 27.8441 million yuan.
Innovative medical management (002173.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
Innovative medical management (002173.SZ): Changjian Investment completed the shareholding of 1.9711 million shares.
On October 9, Gelonhui announced that as of October 9, 2024, the shareholding plan disclosed by Changjian Investment has expired, and the company has received a notification letter from Changjian Investment regarding the progress of the shareholding plan. Changjian Investment has cumulatively reduced 1.9711 million shares, accounting for 0.4467% of the total share capital of the company.
Amoy Diagnostics (300685.SZ): The company's products have entered the special review process for innovative medical instruments.
On October 9th, Amoy Diagnostics (300685.SZ) announced that its independently developed products have recently entered the special review process for innovative medical instruments at the Medical Device Technology Evaluation Center of the State Drug Administration. The HRD test kit is a companion diagnostic product for PARP inhibitors (poly ADP-ribose polymerase inhibitors), a new drug for targeted therapy. PARP inhibitors are a type of targeted drug for multi-gene multi-site mutated tumors with the BRCA gene as the core, covering multiple cancers such as ovarian cancer, prostate cancer, breast cancer, and pancreatic cancer.
Innovative Medical Management Co.,Ltd.'s (SZSE:002173) Business Is Yet to Catch Up With Its Share Price
More Unpleasant Surprises Could Be In Store For Shenzhen Sea Star Technology Co., Ltd.'s (SZSE:002137) Shares After Tumbling 27%No Data
No Data
